J&J Talks Up Wellness As Economy, Generics Shadow ’09
Johnson & Johnson CEO William Weldon emphasized the company's emerging wellness and prevention strategy during a year-end sales and earnings presentation Jan. 20, in which the macroeconomic climate, loss of Risperdal and declining sales of Procrit weighed on the pharmaceutical segment's top line
You may also be interested in...
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.